Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]
Structurally it is built on the GIP backbone rather than the GLP-1 backbone, which is the single fact that explains most of its pharmacology and most of the confusion about it
56.0% 1 More likely to have an obesity diagnosis 69.6% vs
In Mexico, CKD prevalence is alarmingly high and remains a leading cause of morbidity and mortality
US$ 28.24
US$ 28.98
US$ 20.37
US$ 25.14
US$ 25.40
